BR112012004284B8 - ácidos biliares poli-hidroxilados para tratamento de transtornos biliares - Google Patents
ácidos biliares poli-hidroxilados para tratamento de transtornos biliaresInfo
- Publication number
- BR112012004284B8 BR112012004284B8 BR112012004284A BR112012004284A BR112012004284B8 BR 112012004284 B8 BR112012004284 B8 BR 112012004284B8 BR 112012004284 A BR112012004284 A BR 112012004284A BR 112012004284 A BR112012004284 A BR 112012004284A BR 112012004284 B8 BR112012004284 B8 BR 112012004284B8
- Authority
- BR
- Brazil
- Prior art keywords
- bile
- polyhydroxylated
- disorders
- treatment
- bile acids
- Prior art date
Links
- 239000003613 bile acid Substances 0.000 title abstract 4
- 210000000941 bile Anatomy 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010008635 Cholestasis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000007870 cholestasis Effects 0.000 abstract 1
- 231100000359 cholestasis Toxicity 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000007232 portal hypertension Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23675009P | 2009-08-25 | 2009-08-25 | |
| US61/236,750 | 2009-08-25 | ||
| PCT/CA2010/001338 WO2011022838A1 (en) | 2009-08-25 | 2010-08-25 | Polyhydroxylated bile acids for treatment of biliary disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012004284A2 BR112012004284A2 (pt) | 2017-06-13 |
| BR112012004284B1 BR112012004284B1 (pt) | 2021-01-05 |
| BR112012004284B8 true BR112012004284B8 (pt) | 2021-05-25 |
Family
ID=43627124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012004284A BR112012004284B8 (pt) | 2009-08-25 | 2010-08-25 | ácidos biliares poli-hidroxilados para tratamento de transtornos biliares |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2470553B1 (https=) |
| JP (1) | JP5909774B2 (https=) |
| CN (1) | CN102712672B (https=) |
| AU (1) | AU2010286253A1 (https=) |
| BR (1) | BR112012004284B8 (https=) |
| SG (1) | SG178562A1 (https=) |
| WO (1) | WO2011022838A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013041519A1 (en) | 2011-09-19 | 2013-03-28 | ETH Zürich, ETH Transfer | Ror gamma modulators |
| US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| AU2012328526B2 (en) | 2011-10-28 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| NZ734451A (en) | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| SG11201503697TA (en) * | 2012-11-28 | 2015-06-29 | Intercept Pharmaceuticals Inc | Treatment of pulmonary disease |
| EP2781217A1 (en) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
| JP6556129B2 (ja) * | 2013-08-01 | 2019-08-07 | アメリカ合衆国 | ファルネソイドｘ受容体の阻害剤及び医薬としての使用 |
| CN104523703A (zh) * | 2014-12-24 | 2015-04-22 | 聂飚 | 一种游离脂肪酸转运蛋白小分子抑制物的应用 |
| US12186329B2 (en) | 2018-08-23 | 2025-01-07 | President And Fellows Of Harvard College | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes |
| EP3890745B1 (en) | 2018-12-04 | 2025-11-19 | President and Fellows of Harvard College | Synthetic derivatives of cholic acid 7-sulfate and uses thereof |
| KR102204406B1 (ko) * | 2019-01-23 | 2021-01-18 | (주)샤페론 | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물 |
| CN109762043B (zh) * | 2019-03-06 | 2020-07-24 | 华南理工大学 | 鹅去氧胆酸及其制备方法 |
| KR20250171471A (ko) | 2019-05-10 | 2025-12-08 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 장 박테리아 담즙산 대사의 소분자 조정제 |
| CN116925168A (zh) * | 2019-08-23 | 2023-10-24 | 深圳云合医药科技合伙企业(有限合伙) | 胆汁酸衍生物及其组合物和应用 |
| CN110548037B (zh) * | 2019-09-24 | 2023-06-02 | 江西天元药业有限公司 | 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途 |
| CN113024624B (zh) * | 2019-12-25 | 2024-09-10 | 上海科胜药物研发有限公司 | 一种去氧胆酸的合成方法 |
| WO2022233398A1 (en) | 2021-05-04 | 2022-11-10 | Kostner Pharma Gmbh | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
| CN115337312B (zh) * | 2022-08-19 | 2025-06-03 | 金熊药业(珠海横琴)有限公司 | 胆酸复合物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS632932A (ja) * | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| RU2224523C2 (ru) * | 1998-07-24 | 2004-02-27 | Сео Хонг Ю | Водный раствор, содержащий желчную кислоту, и способ его получения |
| WO2006116814A1 (en) * | 2005-05-02 | 2006-11-09 | Vanadis Bioscience Ltd | Composition and uses thereof |
| US20090232913A1 (en) * | 2005-05-02 | 2009-09-17 | Momir Mikov | Composition for the Control of Cholesterol Levels |
| US20110263546A1 (en) * | 2008-02-26 | 2011-10-27 | Renxue Wang | Polyhydroxylated Bile Acids for Treatment of Biliary Disorders |
-
2010
- 2010-08-25 EP EP10811080.0A patent/EP2470553B1/en active Active
- 2010-08-25 BR BR112012004284A patent/BR112012004284B8/pt active IP Right Grant
- 2010-08-25 JP JP2012525830A patent/JP5909774B2/ja active Active
- 2010-08-25 CN CN201080048314.9A patent/CN102712672B/zh active Active
- 2010-08-25 WO PCT/CA2010/001338 patent/WO2011022838A1/en not_active Ceased
- 2010-08-25 AU AU2010286253A patent/AU2010286253A1/en not_active Abandoned
- 2010-08-25 SG SG2012013132A patent/SG178562A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011022838A1 (en) | 2011-03-03 |
| EP2470553B1 (en) | 2024-06-19 |
| JP5909774B2 (ja) | 2016-04-27 |
| EP2470553A1 (en) | 2012-07-04 |
| BR112012004284B1 (pt) | 2021-01-05 |
| EP2470553A4 (en) | 2013-02-20 |
| JP2013502442A (ja) | 2013-01-24 |
| BR112012004284A2 (pt) | 2017-06-13 |
| EP2470553C0 (en) | 2024-06-19 |
| CN102712672B (zh) | 2016-09-14 |
| CN102712672A (zh) | 2012-10-03 |
| WO2011022838A8 (en) | 2011-06-16 |
| AU2010286253A1 (en) | 2012-04-19 |
| SG178562A1 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012004284B8 (pt) | ácidos biliares poli-hidroxilados para tratamento de transtornos biliares | |
| CY1118452T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
| ECSP099414A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| UA99882C2 (uk) | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) | |
| DE602007005120D1 (de) | 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist | |
| IL196543A (en) | Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders | |
| NI200700296A (es) | Imidazoquinolinas como inhibidores de cinasa de lipido | |
| BRPI0612112A8 (pt) | composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1. | |
| ATE528002T1 (de) | Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden | |
| WO2008021210A3 (en) | Methods and compositions for the treatment of neurodegenerative disorders | |
| NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| CR20110103A (es) | Heteroarilos sustituidos | |
| TW200806325A (en) | Therapeutic uses of inhibitors of RTP801 | |
| SG10201407403UA (en) | Treatments For Gastrointestinal Disorders | |
| PT2056814E (pt) | Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase | |
| MX2009005725A (es) | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. | |
| CY1118966T1 (el) | Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| MX2011010918A (es) | Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2. | |
| WO2010007482A3 (en) | Thiazole derivatives as stearoyl coa desaturase inhibitors | |
| PT2056805E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular | |
| WO2009037542A3 (en) | Spirocyclic compounds as stearoyl coa desaturase inhibitors | |
| BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: RENXUE WANG (CA) , VICTOR LING (CA) , JONATHAN AHA |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: RENXUE WANG (CA) , VICTOR LING (CA) , JONATHAN AHA |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: QING BILE THERAPEUTICS INC. (CA) Free format text: ANULADA A PUBLICACAO CODIGO 25.3 NA RPI NO 2458 DE 14/02/2018 POR TER SIDO INDEVIDA. Owner name: QING BILE THERAPEUTICS INC. (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: QING BILE THERAPEUTICS INC. (CA) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |